Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Balvinder Bharj

Optometrist Jersey City, NJ Doctor of Optometry

NPI 1871967356 CMS profile 1375079

20 Mall Drive East, Lenscrafters Macys, Jersey City, NJ 07310

Open in the dashboard

General payments

$7,205

98 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Balvinder Bharj of Jersey City, NJ is reported in the CMS Open Payments database as having received $7,205 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,500 27
2024 General $2,270 20
2023 General $173 3
2022 General $661 8
2021 General $484 11
2020 General $542 14
2019 General $1,575 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Balvinder Bharj
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Balvinder Bharj were reported at $1,500. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Balvinder Bharj Optometrist median Middle half National median
2019 $1,575 $159 $67–$371 $163
2020 $542 $72 $29–$165 $114
2021 $484 $125 $46–$292 $132
2022 $661 $162 $66–$374 $149
2023 $173 $177 $72–$406 $160
2024 $2,270 $188 $77–$427 $164
2025 $1,500 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Vision Care, Inc. $4,380 50 payments
  2. Bausch & Lomb Americas Inc. $662 13 payments
  3. Tarsus Pharmaceuticals, Inc. $536 8 payments
  4. CooperVision Inc. $479 8 payments
  5. Alcon Vision LLC $353 9 payments
  6. Sun Pharmaceutical Industries Inc. $175 4 payments
  7. Johnson & Johnson Surgical Vision, Inc. $139 1 payment
  8. Harrow Eye, LLC $124 1 payment
  9. Aerie Pharmaceuticals, Inc. $122 1 payment
  10. AbbVie, Inc. $120 1 payment
  11. Other $115 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,345 93 payments
  2. Travel and Lodging $1,841 4 payments
  3. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. Acuvue $4,231 47 payments
  2. XDEMVY $423 7 payments
  3. INFUSE $412 11 payments
  4. Precision 1 $347 8 payments
  5. MiSight Contact Lens $279 4 payments
  6. MIEBO $250 2 payments
  7. XIIDRA $250 2 payments
  8. Cequa $175 4 payments
  9. Ortho-K Contact Lens $154 2 payments
  10. DAILIES TOTAL1 $150 2 payments
  11. Other $1,028 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record